Developer docs
API playgroundTry for free, no card

Search company profiles

Oasis Diagnostics

Full company profile

uuid000dsk2

Namestring
Oasis Diagnostics
Legal namestring
Oasis Diagnostics Corporation
Websiteurl
4saliva.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Oasis Diagnostics Corporation is a privately held, bootstrapped developer and manufacturer of non-invasive saliva and oral fluid collection devices and point-of-care testing tools, founded in 2002 and headquartered in Vancouver, Washington. The company sells Research Use Only (RUO) products spanning a portfolio of more than a dozen proprietary collection kits — including SuperSAL, SuperSAL 2, PureSAL, RNAProSAL, SimplOFy, DNA SAL, MicroSAL (for children and animals), AccuSAL, VersiSAL, FemCollect, and PediaSAL — engineered around a cylindrical absorbent pad architecture with a built-in Sample Volume Adequacy Indicator. Its VerOFy point-of-care platform pairs rapid saliva collection with immunochromatographic test strips and the LIAM Bluetooth-enabled portable reader for quantitative result capture. Beyond proprietary devices, Oasis generates distribution revenue as the exclusive North American distributor for ViennaLab Diagnostics assays (StripAssay and RealFast PCR products) and as authorized representative for Operon S.A. PCR-based genomic strip assays, and offers end-to-end custom product development services through a 23+ year partnership with Giddings Product Development.

The company's go-to-market combines direct B2B sales via its 4saliva.com catalog (with "Request Information" forms replacing public pricing) with channel partnerships for genomic assay distribution and emerging-market deployment, most recently through Oludent Health International across Africa, the Middle East, and Asia. Customer segments are horizontally diversified across diagnostics and biotechnology companies, contract research organizations, academic and clinical research laboratories, healthcare providers (including Alzheimer's Association NEWIDEAS and Worldwide FINGERS collaborations), and veterinary researchers. Oasis supplements device sales with an internal Oasis Research Lab offering fertility, steroid, and stress/fatigue biomarker panels (17β-estradiol, progesterone, testosterone, DHEA, DHEAS, cortisol, IL1β, TNF, IgA).

Oasis has issued patents across the US, EU, and international markets covering its oral fluid collection and testing products, and is led by CEO Paul Slowey. Recent strategic activity through 2025-2026 — including the SuperSAL 2 product launch, at-home cancer screening co-development with UCM Technologies, and the multi-party Tri-Engine Execution Model consortium for community health systems in Africa — signals an expansion from a niche RUO consumables vendor toward a platform player spanning consumer screening, emerging-market public health, and research tools, though all products remain research-use-only with no FDA-cleared diagnostic claims in the disclosed material.

Short descriptiontext

Oasis Diagnostics Corporation develops and manufactures proprietary non-invasive saliva and oral fluid collection devices (SuperSAL, PureSAL, RNAProSAL, VerOFy/LIAM) and distributes ViennaLab and Operon genomic assays in North America, serving diagnostics companies, research laboratories, and emerging-market health programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, United States
HQ citystring
Vancouver
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
saliva collection devices, oral fluid diagnostics, point-of-care testing, molecular diagnostics tools, salivary biomarker research
Industry3 codes
PRIMARYHLAAALAM
Sample Collection, Stabilization & Pre-Analytics (biobanking, transport media, extraction kits)
SECONDARYHLAGAEAI
Sample Logistics, Biorepository & IVD Kit Management (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Diagnostic Sample Collection Devices
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Saliva Collection Device Sales
TypeHardware Sales
Description

Sale of proprietary saliva and oral fluid collection devices including SuperSAL, PureSAL, RNAProSAL, DNA SAL, VersiSAL, SimplOFy, MicroSAL, AccuSAL, FemCollect, and PediaSAL kits. Products sold as Research Use Only (RUO).

4saliva.com
2ViennaLab Diagnostics Distribution
TypeLicensing Royalties
Description

Exclusive distributor for ViennaLab Diagnostics products in Canada and United States, including StripAssay and RealFast PCR-based genomic kits for various diseases and conditions.

4saliva.com
3Operon S.A. Products Distribution
TypeLicensing Royalties
Description

Authorized representative for Operon S.A. products including PCR-based genomic strip assays for celiac disease, HPV, and infectious diseases in US and Canada.

4saliva.com
4Custom Product Development
TypeProfessional Services
Description

End-to-end development services from concept through production and packaging for custom saliva collection kits and testing tools, leveraging partnerships with Giddings Product Development.

4saliva.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales
Pricing details1 tier
1Research-use only collection devices with no public pricing
ModelOtherBilling cadencePay-as-you-go
Notes

Products sold For Research Use Only. Contact sales for pricing on SuperSAL, PureSAL, RNAProSAL, DNA SAL, VersiSAL, SimplOFy, MicroSAL, AccuSAL, FemCollect, PediaSAL, and VerOFy kits.

4saliva.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 14 records shown
1VerOFy®
Description

Point-of-care platform for rapid saliva-based testing using lateral flow immunochromatography, latex agglutination, and magnetic beads

4saliva.com
+13 more records
Core offering1 text field

Oasis Diagnostics develops, manufactures, and distributes proprietary saliva and oral fluid collection devices used in molecular diagnostics, proteomic analysis, and point-of-care testing. Its portfolio spans standardized collection kits (e.g., Super•SAL, Pure•SAL, RNAPro•SAL, DNA•SAL, SimplOFy, Micro•SAL, Accu•SAL, Versi•SAL, Fem•Collect, Pedia•SAL) plus the VerOFy® point-of-care platform with the LIAM™ Bluetooth reader. The company is also the exclusive North American distributor for ViennaLab Diagnostics genomic assays (StripAssay®, RealFast™) and the authorized US/Canada representative for Operon S.A. PCR-based genomic tests, and offers custom device development and salivary biomarker research services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Products used by Alzheimer's Association NEWIDEAS study and Worldwide FINGERS Project for biomarker research
+2 more records
Product overview1 text field

Oasis Diagnostics® offers a comprehensive portfolio of non-invasive saliva and oral fluid collection devices for molecular, proteomic, and point-of-care diagnostics applications. The core product line includes standardized collection kits (Super•SAL 2™, Super•SAL™, Pure•SAL™, RNAPro•SAL™, SimplOFy™, DNA•SAL™, Micro•SAL™ for Children/Animals, Accu•SAL™, Versi•SAL®, Fem•Collect™, Pedia•SAL™) and the VerOFy®/LIAM™ point-of-care testing platform. The company also distributes ViennaLab Diagnostics genomic assays (StripAssay®, RealFast™) and Operon S.A. PCR-based products, while offering custom product development services and research lab biomarker panels for fertility, steroid, and stress biomarkers. All products are for research use only.

Product and service2 records
1Super•SAL 2™ Universal Saliva Collection Kit
CategorySaliva collection device
Description

Universal saliva collection kit (Catalog Number SSAL-601) for standardized whole saliva sampling that collects ~1 mL in 1-5 minutes via a highly absorbent cylindrical pad placed along the side of the tongue. Built-in Sample Volume Adequacy Indicator and patented compression tube system; for research use only.

2Super•SAL™ Universal Saliva Collection Kit
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-24
Description

Strategic partnership to expand saliva-based diagnostics in Africa, the Middle East, and Asia. Initiative aims to deploy early detection, point-of-care screening, and affordable testing solutions in emerging markets through the 360UNCOVER movement and Tri-Engine Execution Model.

2UCM Technologies
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-10
Description

Partnership to develop at-home saliva collection test for next-generation cancer screening. Combines Oasis saliva collection technology with UCM's biomarker assay CA-62 for early cancer detection. Initial validation studies planned for 2025-26.

einpresswire.com
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Exclusive North American distributor (Canada and United States) for ViennaLab Diagnostics assays including KRAS, BRAF, Alzheimer's, CVD, and pharmacogenomic tests based on StripAssay and RealFast PCR technologies.

4Operon S.A.
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Authorized representative for Operon S.A. products in United States and Canada. Products include genomic strip tests for celiac disease, AZF micro-deletions, HPV, and infectious diseases (Chlamydia, HSV, Neisseria gonorrhoeae).

4saliva.com
5Giddings Product Development (GPD)
Strategic tierMajorTypeStrategic or Co-development Partner
Description

Longstanding partnership since Oasis founding over 23 years ago. Led by Jason Giddings, providing deep technical skill and engineering precision for custom product development including design, CAD, prototyping, tooling, manufacturing, assembly, and packaging.

4saliva.com
6Queensway Medical Training College
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Consortium partner in Tri-Engine Execution Model launched January 14, 2026 in Nairobi, Kenya. Partnership focuses on early detection, workforce development, and health system integration for community-based health systems in Africa.

southcoasttoday.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Consortium partner in Tri-Engine Execution Model for scaling community-based health systems in Africa. Focuses on moving health innovation beyond pilots into scalable, country-level deployment with Kenya as first execution node.

8Dr. Elizabeth (Birdie) Shirtcliff
Strategic tierMinorTypeOthers
Description

Scientific advisor; Editor-in-chief of Psychoneuroendocrinology and research professor at University of Oregon. Longstanding collaborator with Oasis Diagnostics using noninvasive biospecimens including saliva for stress-responsive hormones research.

4saliva.com
9Professor Chamindie Punyadeera
Strategic tierMinorTypeOthers
Description

Scientific advisor; Innovator in salivary diagnostics and liquid biopsy laboratory at Griffith University for biomarker development from concept to commercialization. Leading women's health and precision health research.

4saliva.com
10Dr. Chi Udeh-Momoh
Strategic tierMinorTypeOthers
Description

Scientific advisor; Translational Neuroscientist at Wake Forest University School of Medicine. Founding Chair of Saliva Biomarkers for Dementia Research workgroup (Alzheimer's Association ISTAART). Co-Leads World-Wide FINGERS Biomarker Consortium.

4saliva.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in oral fluid collection and rapid diagnostics (Intercept, OraQuick). Competes with Oasis in saliva-based specimen collection and infectious disease/point-of-care testing.

TypeBroad incumbent
Description

Animal and food safety diagnostics with emerging genomics offerings. Comparable through veterinary diagnostics use cases (MicroSAL for Animals) and broader diagnostics distribution model.

TypeDirect peer
Description

Maker of iSWAB collection kits — Oasis is an existing distribution partner for the iSWAB Microbiome kit. Directly comparable in non-invasive sample collection products and applications.

TypeBroad incumbent
Description

Major IVD platform with broad molecular diagnostics, oncology screening, and saliva-based test offerings (e.g., cobas). Relevant comparable as scale-of-execution benchmark for Oasis's emerging at-home cancer screening ambitions.

TypeBroad incumbent
Description

Large established provider of sample technologies and molecular diagnostics. Overlaps with Oasis in pre-analytical/sample collection consumables across PCR, sequencing, and IVD workflows.

TypeDirect peer
Description

Saliva-based biomarker testing lab and saliva collection device provider (SalivaBio). Closely comparable in salivary biomarker discovery services and collection devices for stress/hormone research.

TypeBroad incumbent
Description

Diversified life sciences tools and diagnostics leader. Comparable in sample collection/pre-analytical consumables, molecular diagnostics kits, and laboratory equipment across research and clinical channels.

TypeOthers
Description

Oasis is the exclusive NA distributor for ViennaLab's StripAssay and RealFast PCR kits. As a supplier-partner rather than direct competitor, ViennaLab is an ecosystem comparable for molecular diagnostics kit manufacturing.

9Spectrum Solutions
TypeDirect peer
Description

Saliva collection device manufacturer (SDNA-1000) used widely for COVID-19 and genetic testing. Direct comparable in product, regulatory positioning, and molecular diagnostics customer base.

TypeDirect peer
Description

Direct competitor in saliva-based DNA/RNA collection devices (Oragene, ORAcollect). Most directly comparable in product, customer base (research/diagnostics), and geographic focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oasis Diagnostics

Diagnostic Sample Collection Devices4saliva.com

Oasis Diagnostics Corporation develops and manufactures proprietary non-invasive saliva and oral fluid collection devices (SuperSAL, PureSAL, RNAProSAL, VerOFy/LIAM) and distributes ViennaLab and Operon genomic assays in North America, serving diagnostics companies, research laboratories, and emerging-market health programs.

What Oasis Diagnostics does

Oasis Diagnostics Corporation is a privately held, bootstrapped developer and manufacturer of non-invasive saliva and oral fluid collection devices and point-of-care testing tools, founded in 2002 and headquartered in Vancouver, Washington. The company sells Research Use Only (RUO) products spanning a portfolio of more than a dozen proprietary collection kits — including SuperSAL, SuperSAL 2, PureSAL, RNAProSAL, SimplOFy, DNA SAL, MicroSAL (for children and animals), AccuSAL, VersiSAL, FemCollect, and PediaSAL — engineered around a cylindrical absorbent pad architecture with a built-in Sample Volume Adequacy Indicator. Its VerOFy point-of-care platform pairs rapid saliva collection with immunochromatographic test strips and the LIAM Bluetooth-enabled portable reader for quantitative result capture. Beyond proprietary devices, Oasis generates distribution revenue as the exclusive North American distributor for ViennaLab Diagnostics assays (StripAssay and RealFast PCR products) and as authorized representative for Operon S.A. PCR-based genomic strip assays, and offers end-to-end custom product development services through a 23+ year partnership with Giddings Product Development.

The company's go-to-market combines direct B2B sales via its 4saliva.com catalog (with "Request Information" forms replacing public pricing) with channel partnerships for genomic assay distribution and emerging-market deployment, most recently through Oludent Health International across Africa, the Middle East, and Asia. Customer segments are horizontally diversified across diagnostics and biotechnology companies, contract research organizations, academic and clinical research laboratories, healthcare providers (including Alzheimer's Association NEWIDEAS and Worldwide FINGERS collaborations), and veterinary researchers. Oasis supplements device sales with an internal Oasis Research Lab offering fertility, steroid, and stress/fatigue biomarker panels (17β-estradiol, progesterone, testosterone, DHEA, DHEAS, cortisol, IL1β, TNF, IgA).

Oasis has issued patents across the US, EU, and international markets covering its oral fluid collection and testing products, and is led by CEO Paul Slowey. Recent strategic activity through 2025-2026 — including the SuperSAL 2 product launch, at-home cancer screening co-development with UCM Technologies, and the multi-party Tri-Engine Execution Model consortium for community health systems in Africa — signals an expansion from a niche RUO consumables vendor toward a platform player spanning consumer screening, emerging-market public health, and research tools, though all products remain research-use-only with no FDA-cleared diagnostic claims in the disclosed material.

Oasis Diagnostics firmographics

Firmographics
Name
Oasis Diagnostics
Legal name
Oasis Diagnostics Corporation
Website
https://4saliva.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
Oasis Diagnostics Corporation develops and manufactures proprietary non-invasive saliva and oral fluid collection devices (SuperSAL, PureSAL, RNAProSAL, VerOFy/LIAM) and distributes ViennaLab and Operon genomic assays in North America, serving diagnostics companies, research laboratories, and emerging-market health programs.
Ownership category
akta.pro rank

Oasis Diagnostics industry classification

Industry
Product category
Diagnostic Sample Collection Devices
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAAALAM
Sample Collection, Stabilization & Pre-Analytics (biobanking, transport media, extraction kits)
SECONDARYHLAGAEAI
Sample Logistics, Biorepository & IVD Kit Management (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Saliva collection devices
  • Oral fluid diagnostics
  • Point-of-care testing
  • Molecular diagnostics tools
  • Salivary biomarker research

Where Oasis Diagnostics is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Oasis Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales

Revenue model

  1. Saliva Collection Device Sales: Sale of proprietary saliva and oral fluid collection devices including SuperSAL, PureSAL, RNAProSAL, DNA SAL, VersiSAL, SimplOFy, MicroSAL, AccuSAL, FemCollect, and PediaSAL kits. Products sold as Research Use Only (RUO).
  2. ViennaLab Diagnostics Distribution: Exclusive distributor for ViennaLab Diagnostics products in Canada and United States, including StripAssay and RealFast PCR-based genomic kits for various diseases and conditions.
  3. Operon S.A. Products Distribution: Authorized representative for Operon S.A. products including PCR-based genomic strip assays for celiac disease, HPV, and infectious diseases in US and Canada.
  4. Custom Product Development: End-to-end development services from concept through production and packaging for custom saliva collection kits and testing tools, leveraging partnerships with Giddings Product Development.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goResearch-use only collection devices with no public pricing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Oasis Diagnostics product offering

Product offering

Core offering

Oasis Diagnostics develops, manufactures, and distributes proprietary saliva and oral fluid collection devices used in molecular diagnostics, proteomic analysis, and point-of-care testing. Its portfolio spans standardized collection kits (e.g., Super•SAL, Pure•SAL, RNAPro•SAL, DNA•SAL, SimplOFy, Micro•SAL, Accu•SAL, Versi•SAL, Fem•Collect, Pedia•SAL) plus the VerOFy® point-of-care platform with the LIAM™ Bluetooth reader. The company is also the exclusive North American distributor for ViennaLab Diagnostics genomic assays (StripAssay®, RealFast™) and the authorized US/Canada representative for Operon S.A. PCR-based genomic tests, and offers custom device development and salivary biomarker research services.

Product overview

Oasis Diagnostics® offers a comprehensive portfolio of non-invasive saliva and oral fluid collection devices for molecular, proteomic, and point-of-care diagnostics applications. The core product line includes standardized collection kits (Super•SAL 2™, Super•SAL™, Pure•SAL™, RNAPro•SAL™, SimplOFy™, DNA•SAL™, Micro•SAL™ for Children/Animals, Accu•SAL™, Versi•SAL®, Fem•Collect™, Pedia•SAL™) and the VerOFy®/LIAM™ point-of-care testing platform. The company also distributes ViennaLab Diagnostics genomic assays (StripAssay®, RealFast™) and Operon S.A. PCR-based products, while offering custom product development services and research lab biomarker panels for fertility, steroid, and stress biomarkers. All products are for research use only.

Differentiator

Problem solved

Functional benefit

Brands

  • VerOFy®: Point-of-care platform for rapid saliva-based testing using lateral flow immunochromatography, latex agglutination, and magnetic beads
  • LIAM™
  • Versi•SAL®
  • DNA•SAL™
  • Super•SAL™
  • RNAPro•SAL™
  • Pure•SAL™
  • SimplOFy™
  • Accu•SAL™
  • Pedia•SAL™
  • Micro•SAL™
  • Fem•Collect™
  • ViennaLab
  • Operon S.A.

Products and services

  • Super•SAL 2™ Universal Saliva Collection Kit Universal saliva collection kit (Catalog Number SSAL-601) for standardized whole saliva sampling that collects ~1 mL in 1-5 minutes via a highly absorbent cylindrical pad placed along the side of the tongue. Built-in Sample Volume Adequacy Indicator and patented compression tube system; for research use only.
  • Super•SAL™ Universal Saliva Collection Kit

Quantifiable outcome

  • Products used by Alzheimer's Association NEWIDEAS study and Worldwide FINGERS Project for biomarker research
  • +2 more outcomes

Companies that use Oasis Diagnostics

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Oasis Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Oasis Diagnostics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, major and minor.

  • Oludent Health InternationalcoreStrategic or Co-development Partner · 24 November 2025Strategic partnership to expand saliva-based diagnostics in Africa, the Middle East, and Asia. Initiative aims to deploy early detection, point-of-care screening, and affordable testing solutions in emerging markets through the 360UNCOVER movement and Tri-Engine Execution Model.
  • UCM TechnologiescoreStrategic or Co-development Partner · 10 November 2025Partnership to develop at-home saliva collection test for next-generation cancer screening. Combines Oasis saliva collection technology with UCM's biomarker assay CA-62 for early cancer detection. Initial validation studies planned for 2025-26.
  • ViennaLab DiagnosticscoreChannel Partner/ Reseller/ DistributorExclusive North American distributor (Canada and United States) for ViennaLab Diagnostics assays including KRAS, BRAF, Alzheimer's, CVD, and pharmacogenomic tests based on StripAssay and RealFast PCR technologies.
  • Operon S.A.majorChannel Partner/ Reseller/ DistributorAuthorized representative for Operon S.A. products in United States and Canada. Products include genomic strip tests for celiac disease, AZF micro-deletions, HPV, and infectious diseases (Chlamydia, HSV, Neisseria gonorrhoeae).
  • Giddings Product Development (GPD)majorStrategic or Co-development PartnerLongstanding partnership since Oasis founding over 23 years ago. Led by Jason Giddings, providing deep technical skill and engineering precision for custom product development including design, CAD, prototyping, tooling, manufacturing, assembly, and packaging.
  • Queensway Medical Training CollegecoreStrategic or Co-development PartnerConsortium partner in Tri-Engine Execution Model launched January 14, 2026 in Nairobi, Kenya. Partnership focuses on early detection, workforce development, and health system integration for community-based health systems in Africa.
  • 360DisruptioncoreStrategic or Co-development PartnerConsortium partner in Tri-Engine Execution Model for scaling community-based health systems in Africa. Focuses on moving health innovation beyond pilots into scalable, country-level deployment with Kenya as first execution node.
  • Dr. Elizabeth (Birdie) ShirtcliffminorOthersScientific advisor; Editor-in-chief of Psychoneuroendocrinology and research professor at University of Oregon. Longstanding collaborator with Oasis Diagnostics using noninvasive biospecimens including saliva for stress-responsive hormones research.
  • Professor Chamindie PunyadeeraminorOthersScientific advisor; Innovator in salivary diagnostics and liquid biopsy laboratory at Griffith University for biomarker development from concept to commercialization. Leading women's health and precision health research.
  • Dr. Chi Udeh-MomohminorOthersScientific advisor; Translational Neuroscientist at Wake Forest University School of Medicine. Founding Chair of Saliva Biomarkers for Dementia Research workgroup (Alzheimer's Association ISTAART). Co-Leads World-Wide FINGERS Biomarker Consortium.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Oasis Diagnostics competitors and assessment

Company assessment

Direct peers

  • OraSure Technologies: Pioneer in oral fluid collection and rapid diagnostics (Intercept, OraQuick). Competes with Oasis in saliva-based specimen collection and infectious disease/point-of-care testing.
  • MAWI DNA Technologies: Maker of iSWAB collection kits — Oasis is an existing distribution partner for the iSWAB Microbiome kit. Directly comparable in non-invasive sample collection products and applications.
  • Salimetrics: Saliva-based biomarker testing lab and saliva collection device provider (SalivaBio). Closely comparable in salivary biomarker discovery services and collection devices for stress/hormone research.
  • Spectrum Solutions: Saliva collection device manufacturer (SDNA-1000) used widely for COVID-19 and genetic testing. Direct comparable in product, regulatory positioning, and molecular diagnostics customer base.
  • DNA Genotek (Oracle Health): Direct competitor in saliva-based DNA/RNA collection devices (Oragene, ORAcollect). Most directly comparable in product, customer base (research/diagnostics), and geographic focus.

Broad incumbents

  • Neogen Corporation: Animal and food safety diagnostics with emerging genomics offerings. Comparable through veterinary diagnostics use cases (MicroSAL for Animals) and broader diagnostics distribution model.
  • Roche Diagnostics: Major IVD platform with broad molecular diagnostics, oncology screening, and saliva-based test offerings (e.g., cobas). Relevant comparable as scale-of-execution benchmark for Oasis's emerging at-home cancer screening ambitions.
  • QIAGEN: Large established provider of sample technologies and molecular diagnostics. Overlaps with Oasis in pre-analytical/sample collection consumables across PCR, sequencing, and IVD workflows.
  • Thermo Fisher Scientific: Diversified life sciences tools and diagnostics leader. Comparable in sample collection/pre-analytical consumables, molecular diagnostics kits, and laboratory equipment across research and clinical channels.

Others

  • ViennaLab Diagnostics: Oasis is the exclusive NA distributor for ViennaLab's StripAssay and RealFast PCR kits. As a supplier-partner rather than direct competitor, ViennaLab is an ecosystem comparable for molecular diagnostics kit manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Oasis Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oasis Diagnostics leadership team

Management profile

Number of profiles

Profiles1 record

Oasis Diagnostics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oasis Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oasis Diagnostics

What does Oasis Diagnostics do?

Oasis Diagnostics develops, manufactures, and distributes proprietary saliva and oral fluid collection devices used in molecular diagnostics, proteomic analysis, and point-of-care testing. Its portfolio spans standardized collection kits (e.g., Super•SAL, Pure•SAL, RNAPro•SAL, DNA•SAL, SimplOFy, Micro•SAL, Accu•SAL, Versi•SAL, Fem•Collect, Pedia•SAL) plus the VerOFy® point-of-care platform with the LIAM™ Bluetooth reader. The company is also the exclusive North American distributor for ViennaLab Diagnostics genomic assays (StripAssay®, RealFast™) and the authorized US/Canada representative for Operon S.A. PCR-based genomic tests, and offers custom device development and salivary biomarker research services.

Is Oasis Diagnostics a public or private company?

Oasis Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Oasis Diagnostics founded?

Oasis Diagnostics was founded in 2002. It employs 11 to 50 people.

Where is Oasis Diagnostics based?

Oasis Diagnostics is headquartered in Vancouver, United States, in the North America region.

How does Oasis Diagnostics make money?

Four revenue lines are on record. Saliva Collection Device Sales are the primary driver. The others are viennaLab Diagnostics Distribution, operon S.A. Products Distribution and custom Product Development.

Who are Oasis Diagnostics's main competitors?

Direct peers on record are OraSure Technologies, MAWI DNA Technologies, Salimetrics, Spectrum Solutions and DNA Genotek (Oracle Health). Broad incumbents are Neogen Corporation, Roche Diagnostics, QIAGEN and Thermo Fisher Scientific. ViennaLab Diagnostics is listed as an others.

Does Oasis Diagnostics have an API?

No public API is recorded for Oasis Diagnostics.

What industry is Oasis Diagnostics in?

Oasis Diagnostics's product category is Diagnostic Sample Collection Devices. Its primary akta.pro industry code is HLAAALAM, Sample Collection, Stabilization & Pre-Analytics (biobanking, transport media, extraction kits), with a secondary code of HLAGAEAI, Sample Logistics, Biorepository & IVD Kit Management (Trial Support). Its NAICS code is 334516 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AbingdonhealthSmarter, Faster, Further: Engineering Next Generation Point of Care DiagnosticsAbingdon Health outlines the engineering roadmap for next-generation point-of-care diagnostics, emphasizing trends toward smarter, faster, and more accessible testing technologies. The article highlights market growth projections and specific innovations from companies such as Genalyte, Oasis Diagnostics, and Abbott that are driving this decentralization of healthcare.Tout sur les assurances pour bateauxServices-Led FDI: The Missing Link in Accelerating National Economic StrategyDr. Anjo De Heus argues that services-led FDI, which brings market-ready companies into local ecosystems, accelerates economic impact faster than traditional FDI. He cites healthcare solutions like Oasis Diagnostics and MedScribe AI as examples, and urges governments to create co-investment vehicles to support such pipelines.PR NewswireAdvanced Materials for Vaginal Self-Collection Enabling High-Quality DNA Isolation, Upcoming Webinar Hosted by XtalksXtalks has announced a free webinar scheduled for March 17, 2026, focused on how advanced material design can improve DNA recovery from vaginal self-collection devices used in HPV screening and other diagnostic applications. Experts from Porex and Oasis Diagnostics will present findings on high-release porous media, including results from a pilot study demonstrating material-driven design impacts on DNA yield and purity. The webinar will also cover saliva sampling applications and provide guidance for device developers selecting materials for non-invasive sample collection workflows.New Bedford Standard-TimesFrom Pilots to Execution: Multi-Partner Platform Launches to Scale Community-Based Health Systems in AfricaA consortium of healthcare, diagnostics, and workforce development partners formally launched an execution-led platform called the Tri-Engine Execution Model in Nairobi, Kenya on January 14, 2026, designed to move Africa’s health innovation ecosystem beyond pilots into scalable, country-level deployment. The partnership brings together Queensway Medical Training College, Oasis Diagnostics, Oludent Health International, and 360Disruption under a signed Memorandum of Understanding to focus on early detection, workforce development, and health system integration. Kenya has been selected as the first execution node, with the platform structured for replication across additional African countries through engagement with governments, development partners, and multilateral institutions.openPR.comFrom Pilots to Execution: Multi-Partner Platform Launches to Scale Community-Based Health Systems in AfricaA consortium of healthcare, diagnostics, and workforce development partners formally launched an execution-led platform called the Tri-Engine Execution Model, signing a Memorandum of Understanding to move Africa's health innovation ecosystem from pilots to scalable, country-level deployment. The partnership brings together Queensway Medical Training College, Oasis Diagnostics, Oludent Health International, and 360Disruption, with Kenya selected as the first execution node for workforce onboarding and community-based deployment using saliva-based diagnostics. The platform is designed as a repeatable framework for adoption by governments and multilateral institutions across additional African countries.MediumBuilding What Matters: Why Advanced Diagnostics Must Create Jobs, Not Just DataA partnership between Oasis Diagnostics, Oludent Health International, and 360Disruption is undertaking a large-scale effort to deploy advanced diagnostics in Africa, focusing on creating local jobs, building national capabilities, and supporting economic participation. The initiative aims to move beyond pilot projects to systemic, impactful solutions that integrate technology with local health systems.MediumWhat If We Solved Disease Before It Spikes?An advocacy piece by 360Disruption proposes a tripartite partnership with Oasis Diagnostics and Oludent Health International to deploy saliva-based diagnostics across Africa as a population-level prevention tool. The proposal frames disease detection not as a technology problem but as a deployment challenge, arguing that non-invasive, low-cost saliva testing paired with local manufacturing, telehealth, and community health workers could create jobs, retain healthcare spending locally, and reduce long-term treatment costs. The initiative is presented as infrastructure-building rather than aid, with an open invitation to development banks, global foundations, and impact investors to co-build national diagnostic capacity.Tout sur les assurances pour bateauxWhat If We Solved Disease Before It Spikes?A blog post by Dr. Anjo De Heus of 360Disruption proposes a tripartite partnership with Oasis Diagnostics and Oludent Health International to deploy saliva-based diagnostics as a population-level prevention tool across Africa.Medium🚀 360UNCOVER — A Movement to Build Diagnostic Sovereignty Across Africa360UNCOVER is a newly launched initiative within the 360Disruption platform aimed at establishing diagnostic sovereignty across African nations by facilitating access to world-class diagnostic technologies, enabling local manufacturing, and building national diagnostic pathways with government, university, and clinic partnerships. Oasis Diagnostics Corporation serves as a cornerstone partner, providing saliva-based molecular and multi-omic testing capabilities designed for non-invasive diagnostics at population scale across all ages and species. The initiative positions itself as an open-architecture movement inviting governments, diagnostic innovators, philanthropies, and technology companies to collaborate toward building Africa's health diagnostic capacity and supply chain ownership.